Semaglutide (GLP-1, healthspan)

metabolic glycemic

Approved medicine for another condition in 8 of 9 markets tracked; in clinical trials in 1.

Evidence so far is from 1 human trial with no pre-planned main endpoint and animal studies.

In people: 1 trial (2,970 people, 2 years). Doses studied: 2.4 mg.

Evidence map

each mark is a study; size shows participants; hover, tap or focus for details

main endpoints improvedno effectworsenedmixedobservationalanother intervention, contextsize not reported

Higher rows are closer to a person taking this. A case that rests only on the lower rows rests on animals or cells.

What each study measured

outlined square: the main (primary) endpoint

Harms reported

human studies

Where it is available

by regulator; select a market for its source

If you are tracking this yourself

measures the human studies used, by how repeatable they are

Repeatability is whether the same person measured twice gets the same number. It is not statistical significance. It informs study or protocol design only, never advice for a person.

What would change this picture

each study's own statement

Trials under way

Every study (5)

T6 Jiménez-Mausbach 2026 Semaglutide and proteomic dementia risk signature in the SELECT trial doi:10.1002/dad2.70432
T3 Feng 2026 Late-life semaglutide treatment slows ageing and extends lifespan in female mice doi:10.1038/s41586-026-10940-7
T3 M.D. 2026 Comparative effects of semaglutide tirzepatide and retatrutide on renal fibrosis in UUO and aged mice doi:10.1016/j.isci.2026.117174
TX Aman 2025 Semaglutide alleviates knee osteoarthritis pain in persons with obesity doi:10.1038/s43587-025-00809-1
TX Alhowail 2026 Semaglutide in cognitive dysfunction: neuroprotective potential, clinical trial limitations, and a prevention-focused framework doi:10.3389/fnagi.2026.1851072